Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension

Journal of Steroid Biochemistry and Molecular Biology

Volumn 165, Issue , 2017, Pages 277-292

  Vignozzi, Linda ^a   Morelli, Annamaria ^a   Cellai, Ilaria ^a   Filippi, Sandra ^b   Comeglio, Paolo ^a   Sarchielli, Erica ^a   Maneschi, Elena ^a   Vannelli, Gabriella Barbara ^a   Adorini, Luciano ^c   Maggi, Mario ^a,d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c INTERCEPT PHARMACEUTICALS   (United States)

^d NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

Author keywords

Farnesoid X receptor; Inflammation; Monocrotaline; Obeticholic acid; Pulmonary hypertension

Indexed keywords

ACETYLCHOLINE; FARNESOID X RECEPTOR; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROPRUSSIDE SODIUM; OBETICHOLIC ACID; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR; MESSENGER RNA; MONOCROTALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOPULMONARY PROTECTION; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SELECTIVITY; ENDOTHELIAL MESENCHYMAL TRANSITION; ENDURANCE TRAINING; HEART PROTECTION; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LUNG FIBROSIS; LUNG HISTOLOGY; MALE; MONOCROTALINE-INDUCED PULMONARY HYPERTENSION; NONHUMAN; PULMONARY ARTERY; RAT; RECEPTOR UPREGULATION; TREADMILL TEST; VASCULAR REMODELING; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; EXERCISE TEST; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART; HYPERTENSION, PULMONARY; LUNG; LUNG INJURY; METABOLISM; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CHENODEOXYCHOLIC ACID; EXERCISE TEST; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INFLAMMATION; LUNG; LUNG INJURY; MALE; MONOCROTALINE; ORGAN SIZE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER;

EID: 84997769550     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2016.07.004     Document Type: Article

References (66)

1. [1] Latus, H., Delhaas, T., Schranz, D., Apitz, C., Treatment of pulmonary arterial hypertension in children. Nat. Rev. Cardiol. 12 (2015), 244–254, 10.1038/nrcardio.2015.6.
2. [2] Malenfant, S., Neyron, A.S., Paulin, R., Potus, F., Meloche, J., et al. Signal transduction in the development of pulmonary arterial hypertension. Pulm. Circ. 3 (2013), 278–293, 10.4103/2045-8932.114752.
3. [3] Rabinovitch, M., Guignabert, C., Humbert, M., Nicolls, M.R., Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ. Res. 115 (2014), 165–175, 10.1161/CIRCRESAHA.113.301141.
4. [4] Corbin, J.D., Beasley, A., Blount, M.A., Francis, S.H., High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem. Biophys. Res. Commun. 334 (2005), 930–938.
5. [5] Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., Staels, B., Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89 (2009), 147–191, 10.1152/physrev.00010.2008.
6. [6] Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J. Med. Chem. 45 (2002), 3569–3572.
7. [7] Hirschfield, G.M., Mason, A., Luketic, V., Lindor, K., Gordon, S.C., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148 (2015), 751–761, 10.1053/j.gastro.2014.12.005.
8. [8] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965, 10.1016/S0140-6736(14)61933-4.
9. [9] He, F., Li, J., Mu, Y., Kuruba, R., Ma, Z., et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 98 (2006), 192–199.
10. [10] Zhang, L., Li, T., Yu, D., Forman, B.M., Huang, W., FXR protects lung from lipopolysaccharide-induced acute injury. Mol. Endocrinol. 26 (2012), 27–36, 10.1210/me.2011-0042.
11. [11] Zhou, C., Shi, Y., Li, J., Zhang, W., Wang, Y., et al. The effects oftaurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak. J. Pharm. Sci. 26 (2013), 761–765.
12. [12] Sakuma, F., Miyata, M., Kasukawa, R., Suppressive effect of prostaglandin E1 on pulmonary hypertension induced bymonocrotaline in rats. Lung 177 (1999), 77–88.
13. [13] Cowan, K.N., Heilbut, A., Humpl, T., Lam, C., Ito, S., Rabinovitch, M., Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 6 (2000), 698–702.
14. [14] Kwon, J.H., Kim, K.C., Cho, M.S., Kim, H.S., Sohn, S., Hong, Y.M., An inhibitory effect of tumor necrosis factor-alpha antagonist to gene expression in monocrotaline-induced pulmonary hypertensive rats model. Korean J. Pediatr. 56 (2013), 116–124, 10.3345/kjp.2013.56.3.116.
15. [15] Vignozzi, L., Morelli, A., Filippi, S., Comeglio, P., Chavalmane, A.K., et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J. Sex. Med. 8 (2011), 57–77, 10.1111/j.1743-6109.2010.02073.x.
16. [16] Rodman, D.M., Yamaguchi, T., Hasunuma, K., O'Brien, R.F., McMurtry, I.F., Effects of hypoxia on endothelium-dependent relaxation of rat pulmonary artery. Am. J. Physiol. 258 (1990), L207–214.
17. [17] Vignozzi, L., Filippi, S., Comeglio, P., Cellai, I., Sarchielli, E., et al. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit. Mol. Cell. Endocrinol. 384 (2014), 143–154, 10.1016/j.mce.2014.01.014.
18. [18] Sasaki, Y., Suzuki, H., Itoh, S., Yoshida, H., Kondo, S., et al. K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models. Eur. J. Pharmacol. 689 (2012), 132–138.
19. [19] Okumura, K., Kato, H., Honjo, O., Breitling, S., Kuebler, W.M., et al. Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. J. Mol. Med. (Berl) 93 (2015), 663–674, 10.1007/s00109-015-1251-9.
20. [20] Ye, L., Jiang, Y., Zuo, X., Farnesoid-X-receptor expression in monocrotaline-induced pulmonary arterial hypertension and right heart failure. Biochem. Biophys. Res. Commun. 467 (2015), 164–170, 10.1016/j.bbrc.2015.09.067.
21. [21] Li, T., Chiang, J.Y., Bile acid signaling in metabolic disease and drug therapy. Pharmacol. Rev. 66:October (2014) (2014), 948–983, 10.1124/pr.113.008201.
22. [22] Sanchez, O., Marcos, E., Perros, F., Fadel, E., Tu, L., et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 176 (2007), 1041–1047.
23. [23] Soon, E., Holmes, A.M., Treacy, C.M., Doughty, N.J., Southgate, L., et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122 (2010), 920–927, 10.1161/CIRCULATIONAHA.109.933762.
24. [24] Cracowski, J.L., Chabot, F., Labarère, J., Faure, P., Degano, B., et al. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur. Respir. J. 43 (2014), 915–917, 10.1183/09031936.00151313.
25. [25] Courboulin, A., Tremblay, V.L., Barrier, M., Meloche, J., Jacob, M.H., et al. Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir. Res., 12, 2011, p 128, 10.1186/1465-9921-12-128.
26. [26] Miyata, M., Sakuma, F., Yoshimura, A., Ishikawa, H., Nishimaki, T., Kasukawa, R., Pulmonary hypertension in rats. 2. Role of interleukin-6. Int. Arch. Allergy Immunol. 108 (1995), 287–291.
27. [27] Golembeski, S.M., West, J., Tada, Y., Fagan, K.A., Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 128:Suppl. (6) (2005), 572S–573S.
28. [28] Steiner, M.K., Syrkina, O.L., Kolliputi, N., Mark, E.J., Hales, C.A., Waxman, A.B., Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104 (2009), 236–244, 10.1161/CIRCRESAHA.108.182014.
29. [29] Savale, L., Tu, L., Rideau, D., Izziki, M., Maitre, B., et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir. Res., 10, 2009, 6, 10.1186/1465-9921-10-6.
30. [30] Hashimoto, N., Phan, S.H., Imaizumi, K., Matsuo, M., Nakashima, H., et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am. J. Respir Cell. Mol. Biol. 43 (2010), 161–172, 10.1165/rcmb.2009-0031OC.
31. [31] Kim, K.K., Kugler, M.C., Wolters, P.J., Robillard, L., Galvez, M.G., et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 13180–13185.
32. [32] Díez, M., Musri, M.M., Ferrer, E., Barberà, J.A., Peinado, V.I., Endothelial progenitor cells undergo an endothelial-to-mesenchymal transition-like process mediated by TGFbetaRI. Cardiovasc. Res. 88 (2010), 502–511, 10.1093/cvr/cvq236.
33. [33] Botney, M.D., Bahadori, L., Gold, L.I., Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am. J. Pathol. 144 (1994), 286–295.
34. [34] Perkett, E.A., Lyons, R.M., Moses, H.L., Brigham, K.L., Meyrick, B., Transforming growth factor-beta activity in sheep lung lymph during the development of pulmonary hypertension. J. Clin. Invest. 86 (1990), 1459–1464.
35. [35] Arcot, S.S., Lipke, D.W., Gillespie, M.N., Olson, J.W., Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem. Pharmacol. 46 (1993), 1086–1091.
36. [36] Lu, A., Zuo, C., He, Y., Chen, G., Piao, L., et al. EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF- 1 signaling. J. Clin. Invest. 125 (2015), 1228–1242, 10.1172/JCI77656.
37. [37] Long, L., Crosby, A., Yang, X., Southwood, M., Upton, P.D., et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 119 (2009), 566–576, 10.1161/CIRCULATIONAHA.108.821504.
38. [38] Raizada, M.K., Ferreira, A.J., ACE2: a new target for cardiovascular disease therapeutics. J. Cardiovasc. Pharmacol. 50 (2007), 112–119.
39. [39] Dai, H., Jiang, L., Xiao, Z., Guang, X., ACE2-angiotensin-(1-7)-Mas axis might be a promising therapeutic target for pulmonary arterial hypertension. Nat. Rev. Cardiol., 12 p 374, 2015, 10.1038/nrcardio.2015.6-c1.
40. [40] Shatanawi, A., Romero, M.J., Iddings, J.A., Chandra, S., Umapathy, N.S., et al. Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am. J. Physiol. Cell. Physiol. 300 (2011), C1181–C1192, 10.1152/ajpcell.00328.2010.
41. [41] Mehta, P.K., Griendling, K.K., Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell. Physiol. 292 (2007), C82–97.
42. [42] Li, G., Liu, Y., Zhu, Y., Liu, A., Xu, Y., et al. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung 191 (2013), 327–336, 10.1007/s00408-013-9470-8.
43. [43] Yamazato, Y., Ferreira, A.J., Hong, K.H., Sriramula, S., Francis, J., et al. Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension 54 (2009), 365–371, 10.1161/HYPERTENSIONAHA.108.125468.
44. [44] Dai, H.L., Guo, Y., Guang, X.F., Xiao, Z.C., Zhang, M., Yin, X.L., The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease. Cardiology 124 (2013), 208–212, 10.1159/000346884.
45. [45] Dai, H., Gong, Y., Xiao, Z., Guang, X., Yin, X., Decreased levels of serum Angiotensin-(1-7) in patients with pulmonary arterial hypertension due to congenital heart disease. Int. J. Cardiol. 176 (2014), 1399–1401, 10.1016/j.ijcard.2014.08.021.
46. [46] Grobe, J.L., Sigmund, C.D., Another reason to eat your greens: cardiopulmonary protection by dietary delivery of angiotensin-converting enzyme-2 and angiotensin-(1-7) made in plants. Hypertension 64 (2014), 1182–1183, 10.1161/HYPERTENSIONAHA.114.04075.
47. [47] Shenoy, V., Kwon, K.C., Rathinasabapathy, A., Lin, S., Jin, G., et al. Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. Hypertension 64 (2014), 1248–1259, 10.1161/HYPERTENSIONAHA.114.03871.
48. [48] Guazzi, M., Phillips, S.A., Arena, R., Lavie, C.J., Endothelial dysfunction and lung capillary injury in cardiovascular diseases. Prog. Cardiovasc. Dis. 57 (2015), 454–462, 10.1016/j.pcad.2014.11.003.
49. [49] Ghofrani, H.A., Pepke-Zaba, J., Barbera, J.A., Channick, R., Keogh, A.M., et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43:Suppl. S (2004), 68S–72S.
50. [50] Lang, M., Kojonazarov, B., Tian, X., Kalymbetov, A., Weissmann, N., et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One, 7, 2012, e43433, 10.1371/journal.pone.0043433.
51. [51] Sawamura, F., Kato, M., Fujita, K., Nakazawa, T., Beardsworth, A., Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J. Pharmacol. Sci. 111 (2009), 235–243.
52. [52] Rubin, L.J., Badesch, D.B., Barst, R.J., Galie, N., Black, C.M., et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346 (2002), 896–903.
53. [53] Galiè, N., Brundage, B.H., Ghofrani, H.A., Oudiz, R.J., Simonneau, G., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119 (2009), 2894–2903, 10.1161/CIRCULATIONAHA.108.839274.
54. [54] Yao, J., Li, C.G., Gong, L.K., Feng, C.C., Li, C.Z., et al. Hepatic cytochrome P450?s play a major role in monocrotaline-induced renal toxicity in mice. Acta Pharmacol. Sin. 35 (2014), 292–300, 10.1038/aps.2013.145.
55. [55] Martin, P., Riley, R., Back, D.J., Owen, A., Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br. J. Pharmacol. 153 (2008), 805–819.
56. [56] Ranchoux, B., Antigny, F., Rucker-Martin, C., Hautefort, A., Péchoux, C., et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 131 (2015), 1006–1018, 10.1161/CIRCULATIONAHA.114.008750.
57. [57] Du, L., Sullivan, C.C., Chu, D., Cho, A.J., Kido, M., et al. Signaling molecules in nonfamilial pulmonary hypertension. N. Engl. J. Med. 348 (2003), 500–509.
58. [58] Dewachter, L., Adnot, S., Guignabert, C., Tu, L., Marcos, E., et al. Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension. Eur. Respir. J. 34 (2009), 1100–1110, 10.1183/09031936.00183008.
59. [59] Yang, J., Li, X., Al-Lamki, R.S., Southwood, M., Zhao, J., et al. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ. Res. 107 (2010), 252–262, 10.1161/CIRCRESAHA.109.209940.
60. [60] Sawada, H., Saito, T., Nickel, N.P., Alastalo, T.P., Glotzbach, J.P., et al. Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. J. Exp. Med. 211 (2014), 263–280, 10.1084/jem.20111741.
61. [61] Schermul, R.T., Kreisselmeier, K.P., Ghofrani, H.A., Yilmaz, H., Butrous, G., et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 169 (2004), 39–45.
62. [62] Lee, D.S., Kim, Y.K., Jung, Y.W., Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension. Korean Circ. J. 40 (2010), 659–664, 10.4070/kcj.2010.40.12.659.
63. [63] Yen, C.H., Leu, S., Lin, Y.C., Kao, Y.H., Chang, L.T., et al. Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling. J. Cardiovasc. Pharmacol. 55 (2010), 574–584, 10.1097/FJC.0b013e3181d9f5f4.
64. [64] Schroll, S., Sebah, D., Wagner, M., Popara, V., Pfeifer, M., Blumberg, F., Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil. Respir. Physiol. Neurobiol. 186 (2013), 61–64, 10.1016/j.resp.2012.11.003.
65. [65] Arif, S.A., Poon, H., Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin. Ther. 33 (2011), 993–1004, 10.1016/j.clinthera.2011.06.008.
66. [66] Ali, A.H., Carey, E.J., Lindor, K.D., Recent advances in the develoment of farnesoid X receptor agonists. Ann. Transl. Med., 3 p 5, 2015, 10.3978/j.issn.2305-5839.2014.12.06.